PARITAPREVIR DIHYDRATE

First approved in 2014

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C40H43N7O7S.2H2O
Molecular Weight	801.908
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.[H][C@@]12C[C@]1(NC(=O)[C@]3([H])C[C@H](CN3C(=O)[C@H](CCCCCC=C2)NC(=O)C4=CN=C(C)C=N4)OC5=NC6=C(C=CC=C6)C7=C5C=CC=C7)C(=O)NS(=O)(=O)C8CC8

InChI

InChIKey=AWGQIDLXYMGEEH-RHSIAEQTSA-N

InChI=1S/C40H43N7O7S.2H2O/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37;;/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51);2*1H2/b11-5-;;/t25-,26-,32+,34+,40-;;/m1../s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24517400 | https://www.ncbi.nlm.nih.gov/pubmed/25005190 | http://adisinsight.springer.com/drugs/800029722 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf

Paritaprevir is a potent inhibitor of the NS3/4A protease that rapidly and consistently suppresses HCV. Paritaprevir is metabolized by the Cytochrome P450 isoform 3A (CYP3A); therefore, ritonavir was used concurrently to increase plasma concentrations and to prolong the half-life of this agent allowing for once-daily dosing. Several antiviral regimens combining paritaprevir with other agents have shown impressive results, tolerable side effects, and importantly, provided support of ‘all-oral’ interferon-free regimens against HCV. Paritaprevir monotherapy is discontinued now but paritaprevir is used as a component of Viekira Pak and Technivie for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cytochrome P450 3A4 127 Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24517400	Substrate 661
Hepatitis C virus serine protease, NS3/NS4A 13 Target ID: CHEMBL2095231 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	Inhibitor 8297		0.18 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic hepatitis C virus (genotype 4) infection 2 Sources: https://www.rxabbvie.com/pdf/technivie_pi.pdf	Curative		Approved 8429	TECHNIVIE Approved Use TECHNIVIE is a fixed-dose combination of ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, and ritonavir, a CYP3A inhibitor and is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. Launch Date 2015

C_max

Value	Dose	Co-administered	Analyte	Population
262 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] OMBITASVIR	[NO STEREO] OMBITASVIR	[NO STEREO] PARITAPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
2220 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] OMBITASVIR	[NO STEREO] OMBITASVIR	[NO STEREO] PARITAPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] OMBITASVIR	[NO STEREO] OMBITASVIR	[NO STEREO] PARITAPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2.2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206619lbl.pdf	150 mg 1 times / day steady-state, oral dose: 150 mg route of administration: Oral experiment type: STEADY-STATE co-administered: [NO STEREO] OMBITASVIR	[NO STEREO] OMBITASVIR	[NO STEREO] PARITAPREVIR plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
900 mg single, oral Highest studied dose Dose: 900 mg Route: oral Route: single Dose: 900 mg Sources: https://pubmed.ncbi.nlm.nih.gov/26710243	healthy, 32.9 years (range: 18–55 years) n = 6 Health Status: healthy Age Group: 32.9 years (range: 18–55 years) Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/26710243	Sources: https://pubmed.ncbi.nlm.nih.gov/26710243

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:85188	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:85188
ZINC	ZINC000203757351	http://zinc15.docking.org/substances/ZINC000203757351

PubMed

Title	Date	PubMed
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.	2014	25005190
New antiviral agents for the treatment of hepatitis C: ABT-450.	2014 Apr	24517400
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.	2015 Sep	25937625
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.	2017 Dec	29390377
Ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin for treatment of chronic hepatitis C 1 genotype in the Republic of Belarus.	2017 Sep	29062907
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.	2017 Summer	28948180
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Therapy-Related Severe Anemia.	2018 Apr	29126346
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.	2018 Mar	29325476
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.	2018 Sep	29377566

Patents

Sample Use Guides

In Vivo Use Guide

50, 100 and 200 mg daily for 3 days (each dose in combination with 100 mg ribavirin).

Route of Administration: Oral

In Vitro Use Guide

To determine the breadth of coverage in genotype 1, the activity of Paritaprevir against chimeric replicons containing sequences derived from 11 genotype 1a- and 9 genotype 1b-infected patients was characterized. EC50s ranged from 0.43 to 1.87 nM against the genotype 1a isolates and from 0.033 to 0.087 nM against the genotype 1b isolates, indicating that Paritaprevir can inhibit NS3 proteases across a broad range of genotype 1 isolates.

Name

Type

Language

PARITAPREVIR DIHYDRATE

Common Name

English

ABT-450 DIHYDRATE

Code

English

PARITAPREVIR HYDRATE [JAN]

Common Name

English

PARITAPREVIR DIHYDRATE [MI]

Common Name

English

Code System Code Type Description

PUBCHEM

90479564